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Table III that appeared in the article “Varenicline for Smoking Cessation: A Review of 
the Literature,” by K. Kaur et al (Curr Ther Res Clin Exp. 2009;70:35–54), contained 
errors. The correct table appears below:
Table III. Results of varenicline clinical trials.
 Primary End Point 
Trial (CAR weeks 9–12) CAR weeks 9–24 CAR weeks 9–52
Jorenby et al4 Varenicline 43.9% Varenicline 29.7% Varenicline 23.0%
 Bupropion SR 29.8% Bupropion SR 20.2% Bupropion SR 14.6%
 Placebo 17.6% Placebo 13.2% Placebo 10.3%
Gonzales et al36 Varenicline 44.0% Varenicline 29.5% Varenicline 21.9%
 Bupropion SR 29.5% Bupropion SR 20.7% Bupropion SR 16.1%
 Placebo 17.7% Placebo 10.5% Placebo 8.4%
Tonstad et al37* Varenicline 49.6%  Varenicline 43.6%
 Placebo 36.9%  Placebo 36.9%
Tsai et al38 Varenicline 59.5% Varenicline 46.8%
 Placebo 32.3% Placebo 21.8%
Aubin et al40 Varenicline 55.9% Varenicline 32.4% Varenicline 26.1%
 NRT 43.2% NRT 27.3% NRT 20.3%
CAR = continuous abstinence rate; SR = sustained release; NRT = nicotine replacement therapy.
*Primary end point = CAR weeks 13–24; secondary end point = CAR weeks 13–52.
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